Cowen Group Stock News

Thermo Fisher Scientific Inc. (TMO) CEO Marc Casper on 42nd Annual Cowen Health Care Conference (Transcript)

Amarin Corporation plc (AMRN) CEO Karim Mikhail on Cowen 42nd Annual Health Care Conference (Transcript)

NEW YORK--(BUSINESS WIRE)--DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services and integrated medical mobility solutions, announced today that CEO Stan Vashovsky will present at the Cowen 42nd Annual Health Care Conference on Monday, March 7th at 9:10 AM Eastern Time. To listen to the live event, please contact your Cowen representative with interest. About DocGo DocGo is a leading provider of last-mile mobile care services and integrated medical mobility solutions. Doc

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck to Participate in Cowen’s 42nd Annual Health Care Conference

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42 nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m. ET.

MONROVIA, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics , a clinical-stage cell-therapy company developing a novel class of tumor-reactive engineered natural killer cell-based cancer immunotherapies, today announced that the executive management team will participate in the Cowen''s 42nd Annual Health Care Conference and host meetings with investors between March 7 and March 9, 2022. About CytoImmune Therapeutics, Inc. Founded in 2017, CytoImmune Therapeutics is a clinical-stage biotechnology company, developing a novel class of cancer immunotherapy medicines based on engineered, allogeneic, tumor-reactive natural killer (TRACK-NK TM ) cell therapies for patients with cancer. The cells are engineered to both directly attack cancer cells and broadly stimulate both the innate and adaptive arms of the immune … Full story available on Benzinga.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET. An audio webcast of the panel discussion will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will b

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading virtual behavioral healthcare company, today announced that Doug Braunstein, Chairman of the Board and Interim Chief Executive Officer, and Jennifer Fulk, Chief Financial Officer, will participate in Cowen’s 42nd Annual Health Care Conference, including a fireside chat presentation on Wednesday, March 9, 2022, at 9:50 a.m. ET.

GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen''s 42nd Annual Healthcare…

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a panel discussion titled “ GI/Microbiome ” at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9 th , 2022 at 10:30 a.m. ET.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Kidney Disease/Fibrosis Panel at the Cowen 42 nd Annual Health Care Conference. The panel will be held on Wednesday, March 9, 2022, at 2:10 p.m. ET. A live webcast of the panel will be available on the “Events & Presentations” section of the Company’s website at https://www.kezarlifesciences.com/investors/news-events/ir-calendar . A replay will be available on the Kezar website for 90 days following the event. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets.

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42 nd Annual Health Care Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

BOSTON--(BUSINESS WIRE)--Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Cowen & Co. 42 nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET.

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today that it will participate in a Kidney Disease / Fibrosis panel discussion at the Cowen 42 nd Annual Health Care Conference on Wednesday, March 9, 2022 at 11:10 am PT / 2:10 pm ET.